康为世纪(688426.SH)发布公告，因当前宏观经济状况及公司所处市场环境较公司2024年推出本激励计 划时已发生较大变化，原激励计划设定的业绩考核指标已无法客观反映当前实际经营态势，继续实施本 激励计划难以充分实现激励计划的设计目的和效果。为充分落实对员工的有效激励，保障广大投资者的 合法权益，从公司长远发展和员工切身利益出发，公司决定终止实施本激励计划。 ...

此次激励计划的有效期为自限制性股票授予日起至激励对象获授的限制性股票全部归属或作废失效之日 止，最长不超过48个月。 太力科技(301595.SZ)发布2026年限制性股票激励计划(草案)，拟授予激励对象的限制性股票数量为180 万股，约占本激励计划草案公布日公司股本总额的1.66%。其中首次授予145.00万股，预留35.00万股。 授予价格为25.74元/股。 ...

Core Viewpoint - The company announced the approval of several proposals during the second meeting of the sixth board of directors, including a stock incentive plan and asset impairment provisions [1] Group 1: Stock Incentive Plan - The board approved the partial unlocking of the second phase of the third stock incentive plan, allowing 235,950 shares of restricted stock to be unlocked for five incentive targets [1] - The unlocking period for the restricted stock is set from September 21, 2025, to September 20, 2026 [1] Group 2: Asset Impairment Provisions - The board also approved a proposal to recognize asset impairment provisions for the fiscal year 2025, which will be assessed and recorded reasonably according to regulations [1] - This measure is intended to better reflect the company's financial situation [1]

此次激励计划的有效期为自限制性股票授予日起至激励对象获授的限制性股票全部归属或作废失效之日 止，最长不超过48个月。 太力科技（301595）(301595.SZ)发布2026年限制性股票激励计划(草案)，拟授予激励对象的限制性股票 数量为180万股，约占本激励计划草案公布日公司股本总额的1.66%。其中首次授予145.00万股，预留 35.00万股。授予价格为25.74元/股。 ...

Core Viewpoint - The company has announced the details of its 2024 restricted stock incentive plan, including the grant date, number of shares, and pricing, which aims to motivate and retain key personnel through equity incentives [2][4][7]. Group 1: Incentive Plan Details - The grant date for the restricted stock is set for December 5, 2025, with the registration completion date on January 9, 2026 [2][22]. - A total of 740,000 shares will be granted, representing 0.2872% of the company's total share capital prior to the grant [2][7]. - The grant price for the restricted stock is set at 10.24 yuan per share [2][7]. Group 2: Approval Process - The company held several meetings to approve the incentive plan, including the seventh board meeting on December 20, 2024, and the first extraordinary general meeting of shareholders on February 5, 2025 [3][4][5]. - The plan has undergone verification by the supervisory board and independent financial advisors, ensuring compliance with relevant regulations [3][5][7]. Group 3: Stock Repurchase and Impact - The restricted stock is sourced from shares repurchased from the secondary market, with a total of 7,209,980 shares repurchased, accounting for 2.80% of the company's total share capital [25][24]. - The stock repurchase was conducted at prices ranging from 17.28 yuan to 18.50 yuan per share, with a total expenditure of approximately 129.41 million yuan [25]. Group 4: Performance Assessment and Conditions - The incentive plan includes performance assessment criteria that must be met for the release of the restricted stock, with evaluations conducted annually over three accounting years [15][19]. - Individual performance assessments will be tailored to different roles, with a grading system to determine eligibility for stock release [19][20]. Group 5: Financial Implications - The issuance of restricted stock will not change the total share capital, thus not affecting the earnings per share [23]. - The company will account for the costs associated with the restricted stock in accordance with relevant accounting standards, adjusting for the number of shares eligible for release based on performance metrics [24][25].

Core Viewpoint - The company has announced the completion of the first unlock period for its 2023 restricted stock incentive plan, allowing 189 participants to unlock a total of 2.93964 million shares, which represents 0.47% of the company's total share capital [2][6][10]. Group 1: Incentive Plan Overview - The 2023 restricted stock incentive plan was approved by the company's board on November 15, 2023, and received independent opinions affirming its benefits for the company's sustainable development [2][3]. - The plan was publicly announced from November 16 to November 25, 2023, with no objections raised by employees during the public notice period [3]. - The plan received approval from Anhui Xihu Investment Holding Group Co., Ltd. on December 5, 2023, allowing the company to proceed with the implementation [3][4]. Group 2: Unlock Conditions and Details - The first unlock period for the restricted stock is set to end on January 8, 2026, with 33% of the granted shares eligible for unlocking [6][7]. - A total of 2.93964 million shares will be unlocked for 189 eligible participants, based on the completion of the first unlock conditions [6][10]. - Shares that do not meet the unlock conditions will be repurchased and canceled by the company [7]. Group 3: Board and Legal Opinions - The board's remuneration and assessment committee confirmed that the unlock conditions have been met and that the arrangement complies with relevant regulations [10]. - Legal opinions from Anhui Tianhe Law Firm affirm that the company has fulfilled necessary internal approvals and that the unlock does not violate any laws or regulations [11].

Core Viewpoint - Zhejiang Xidamen New Materials Co., Ltd. has completed the registration of its 2025 Restricted Stock Incentive Plan, granting a total of 3.106 million shares to 105 individuals at a price of 8.27 yuan per share, aimed at enhancing employee motivation and aligning interests with shareholders [2][5][6]. Group 1: Incentive Plan Details - The registration date for the restricted stock is January 8, 2026, with a total of 3.106 million shares registered [2][12]. - The plan was approved through a series of board meetings and internal disclosures, with no objections raised during the public announcement period [3][4]. - The stock is sourced from the company's repurchased A-shares in the secondary market [6]. Group 2: Granting and Vesting Conditions - The grant date for the restricted stock is December 9, 2025, with a total of 3.106 million shares granted to 105 individuals [5][6]. - The vesting period for the restricted stock is set for a maximum of 36 months, with a lock-up period of 12 to 24 months for the granted shares [9][10]. - The plan stipulates that if the vesting conditions are not met, the shares will be repurchased by the company at the grant price [9]. Group 3: Financial Implications - The total funds raised from the incentive plan amount to approximately 25.69 million yuan, which will be used to supplement the company's working capital [11][13]. - The impact of the stock grant on the company's financial statements will be assessed according to the relevant accounting standards, with adjustments made based on the number of shares that can be released from restrictions [13]. Group 4: Shareholder Structure - Following the completion of the stock grant registration, the total share capital of the company remains unchanged at 191,298,100 shares, and the controlling shareholder's ownership percentage remains at 57.59% [13].

Core Viewpoint - The company, Chengdu Olin Biological Technology Co., Ltd., has announced the repurchase and cancellation of 224,700 shares of restricted stock due to unmet performance targets in its 2023 stock incentive plan [2][5]. Group 1: Repurchase and Cancellation Details - The repurchase is based on the failure to meet the performance assessment criteria for the second unlock period of the restricted stock incentive plan [2][5]. - The repurchase price is set at 10.59 yuan per share, plus interest at the bank's current deposit rate [3][6]. - The decision was approved by the board of directors on October 28, 2025, and subsequently ratified by the shareholders on November 14, 2025 [3][4]. Group 2: Impact on Share Capital - Following the cancellation, the total share capital will decrease from 405,933,600 shares to 405,708,900 shares, reflecting a reduction of 224,700 shares [8]. - The remaining number of restricted shares for the eight incentive recipients will be 299,600 shares after the cancellation [6]. Group 3: Compliance and Legal Opinions - The company has complied with relevant laws and regulations regarding the decision-making and disclosure processes for the repurchase [9]. - The legal opinion confirms that the repurchase aligns with the company's incentive plan and applicable regulations [9].

Group 1 - The company held its 14th (temporary) meeting of the 11th Board of Directors on January 9, 2026, to discuss several key resolutions [1][4][61] - The board approved the repurchase and cancellation of 119,700 restricted stocks from five former employees who no longer meet the incentive conditions of the 2021 stock incentive plan [1][28][40] - The board also approved the nomination of Liu Wei as an independent director candidate, who will serve as the chair of the audit committee and a member of the remuneration and assessment committee [5][49] Group 2 - The board approved the revision and establishment of several governance systems to enhance operational standards and comply with relevant laws and regulations [8][53] - The company plans to reduce the registered capital of its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Biotechnology Research Institute, by 22 million yuan, bringing the total registered capital down to 28 million yuan [55][59] - The company applied for a comprehensive credit line of 230 million yuan from Zheshang Bank, which includes a general credit limit of 130 million yuan and a low-risk credit limit of 100 million yuan [61][62] Group 3 - The company will hold its first temporary shareholders' meeting of 2026 on January 27, 2026, to discuss the approved resolutions [21][67] - The meeting will include both on-site and online voting options for shareholders [68][75] - The company ensures that all resolutions comply with the relevant laws and regulations, and the independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange [50][71]

Core Viewpoint - The company has completed the first vesting period of its 2023 restricted stock incentive plan, with a total of 202,000 shares being vested to 29 individuals [3][7][9]. Group 1: Restricted Stock Incentive Plan Details - The number of restricted stock vested in this period is 202,000 shares [2][7]. - The shares are sourced from the company's repurchase of A-share common stock in the secondary market [3][7]. - The decision-making process for the incentive plan involved multiple board and supervisory meetings, with independent directors and the supervisory board providing consent [4][5]. Group 2: Vesting Conditions and Restrictions - For directors and senior management, the transfer of vested shares is limited to 25% of their total holdings annually during their tenure, and they cannot transfer shares within six months after leaving the company [7][8]. - Any profits from buying and selling shares within six months must be returned to the company [7]. - Changes in relevant laws or regulations will affect the transferability of shares for these individuals [8]. Group 3: Financial Impact and Registration - The company received a total of RMB 30,077,800.00 from the 29 individuals for the subscription of the 202,000 shares [9]. - The registration of these shares was completed on January 7, 2026, and the total share capital of the company remains unchanged [9][11]. - The vesting of these shares is not expected to have a significant impact on the company's financial condition or operating results [10][11].